Celularity Inc (CELU)
Celularity Inc. is a healthcare company focused on regenerative and cellular medicines aimed at aging-related and degenerative diseases. The company develops placental-derived, allogeneic cell therapy candidates designed for off-the-shelf use, including programs under Cell Therapy and Degenerative Disease such as PDA-001 for Crohn’s disease and other autoimmune or degenerative conditions, PDA-002 for facioscapulohumeral muscular dystrophy, and pExo-001 for osteoarthritis. Through its BioBanking segment, Celularity also collects, processes, and stores umbilical cord and placental blood and tissue under the LifebankUSA brand. In addition, it produces and licenses products used in surgical and wound care markets, including Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex. The company was founded in 1998 and is headquartered in Florham Park, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CELU
|
$1.86
|
57.3% Upside
|
Bargain
|
Not available
|
Not available
|
Fair
|
0.0%
|
1.4x
|
34.156 M
|
104.7 M
|
68.6%
|
65.2%
|
-17.6
|
14.5%
|
